Answers are grounded in this paper and cite their sources.
Purpose The aim of this study was to investigate whether external-beam accelerated partial-breast irradiation (APBI) provides noninferior local control compared with whole-breast irradiation (WBI). Patients and Methods We conducted this randomized phase III trial (ClinicalTrials.gov identifier: NCT01803958 ) in 35 centers. Patients age ≥49 years with invasive breast cancer, resection margins ≥2 mm, tumor diameter ≤3 cm, and pN0-1 were randomly assigned 1:1 to WBI or APBI (38.5 Gy in 10 fractions twice daily). Neither patients nor investigators were masked to treatment allocation. The primary end point was ipsilateral breast tumor recurrence (IBTR), analyzed according to the modified intention-to-treat analysis. We assumed a 5-year IBTR rate of 4% in the WBI group to exclude a 2% increase in the APBI group (90% power; noninferiority margin hazard ratio [HR], 1.5). Results Between 2007 and 2019, 3,309 patients were randomly assigned (1,652 to APBI, 1,657 to WBI); 84 were excluded from the analysis. The median follow-up was 97.5 months. The 5-year cumulative IBTR incidence was 1.0% (95% CI, 0.6 to 1.6) for APBI and 0.8% (95% CI, 0.5 to 1.4) for WBI. The HR for APBI versus WBI was 1.18 (90% CI, 0.63 to 2.20) with the upper confidence limit crossing the prespecified noninferiority margin. Conclusion At 5 years, the cumulative incidence of IBTR is exceptionally low (≤1%) in both arms. Although formal statistical noninferiority was not demonstrated because the upper confidence limit crossed the margin, the absolute difference was <0.2%. External-beam APBI therefore is a reasonable clinical alternative to WBI for low-risk patients.
No takes yet. Share an insight, caveat, or question.
Meduri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: